{"id":32358,"date":"2025-06-03T17:18:01","date_gmt":"2025-06-03T11:48:01","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32358"},"modified":"2025-06-03T17:18:50","modified_gmt":"2025-06-03T11:48:50","slug":"pharma-news-for-beam-incannex-kura","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura","title":{"rendered":"Beam\u2019s BEAM-302 Earns FDA Orphan Drug Tag for AATD; Incannex\u2019s IHL-42X Moves to Phase III After FDA Protocol OK; Kura and Kyowa Kirin\u2019s Ziftomenib Gets FDA Priority Review in NPM1-Mutant AML; GSK\u2019s Linerixibat NDA Accepted by FDA for PBC-Linked Pruritus; Ascendis\u2019 TransCon CNP Granted FDA Priority Review for Achondroplasia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a093838061bd\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a093838061bd\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura\/#Beam_Therapeutics_Secures_FDA_Orphan_Drug_Designation_for_BEAM-302_in_AATD\" >Beam Therapeutics Secures FDA Orphan Drug Designation for BEAM-302 in AATD<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura\/#Incannex_Healthcare_Advances_IHL-42X_to_Phase_III_After_FDA_Protocol_Clearance\" >Incannex Healthcare Advances IHL-42X to Phase III After FDA Protocol Clearance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura\/#Kura_Oncology_and_Kyowa_Kirin_Gain_FDA_Priority_Review_for_Ziftomenib_NDA_in_NPM1-Mutant_AML\" >Kura Oncology and Kyowa Kirin Gain FDA Priority Review for Ziftomenib NDA in NPM1-Mutant AML<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura\/#GSKs_NDA_for_Linerixibat_Accepted_by_FDA_for_PBC-Related_Cholestatic_Pruritus\" >GSK\u2019s NDA for Linerixibat Accepted by FDA for PBC-Related Cholestatic Pruritus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura\/#Ascendis_Pharmas_TransCon_CNP_Receives_FDA_Priority_Review_for_Achondroplasia\" >Ascendis Pharma&#8217;s TransCon CNP Receives FDA Priority Review for Achondroplasia<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-beam-therapeutics-secures-fda-orphan-drug-designation-for-beam-302-in-aatd\"><span class=\"ez-toc-section\" id=\"Beam_Therapeutics_Secures_FDA_Orphan_Drug_Designation_for_BEAM-302_in_AATD\"><\/span>Beam Therapeutics Secures FDA Orphan Drug Designation for BEAM-302 in AATD<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Beam Therapeutics Inc.<\/strong> announced that the FDA has granted <strong>Orphan Drug Designation<\/strong> to its investigational therapy, <strong>BEAM-302<\/strong>, for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alpha-1-antitrypsin-deficiency-a1atd-market\" class=\"ek-link\">treatment of <strong>alpha-1 antitrypsin deficiency (AATD)<\/strong><\/a><strong>. <\/strong>BEAM-302 is a liver-targeting lipid nanoparticle (LNP) formulation containing a guide RNA and an mRNA encoding a base editor designed to correct the underlying genetic mutation responsible for AATD. The designation provides Beam with potential development incentives, including tax credits, user fee exemptions, and up to seven years of market exclusivity upon approval.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cReceiving orphan drug designation for BEAM-302 is an important milestone in our efforts to bring a transformative therapy to people living with AATD, many of whom currently lack effective long-term treatment options,\u201d said <\/em><strong><em>Giuseppe Ciaramella, Ph.D., president of Beam Therapeutics<\/em><\/strong><em>. \u201cThis recognition by the FDA, following the receipt of RMAT designation from the FDA just weeks ago, highlights the urgency of addressing this serious genetic disease and the potential of BEAM-302 to directly correct the DNA mutation, the underlying root cause of this illness. We are encouraged by the FDA\u2019s continued support of this program and are committed to its advancement to deliver a one-time, potentially curative treatment to patients as quickly and safely as possible.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>BEAM-302 is currently being evaluated in a Phase I\/II clinical trial, with positive early data reported in March 2025. The initial results from the first three single-ascending dose cohorts demonstrated that the therapy was well tolerated and showed dose-dependent correction of the disease-causing mutation. Notably, the 60 mg dose cohort achieved total AAT protein levels above the therapeutic threshold. Dosing in the fourth cohort (75 mg) has begun, with updated data expected in the second half of 2025.<\/p>\n\n\n\n<p>Beam also plans to initiate Part B of the study, which will enroll AATD patients with mild to moderate liver disease, later this year. The company previously secured FDA clearance for its Investigational New Drug (IND) application for BEAM-302 in March 2025 and received Regenerative Medicine Advanced Therapy (RMAT) designation in May 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-incannex-healthcare-advances-ihl-42x-to-phase-iii-after-fda-protocol-clearance\"><span class=\"ez-toc-section\" id=\"Incannex_Healthcare_Advances_IHL-42X_to_Phase_III_After_FDA_Protocol_Clearance\"><\/span>Incannex Healthcare Advances IHL-42X to Phase III After FDA Protocol Clearance<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Incannex Healthcare Inc. <\/strong>announced that its <strong>Phase III RePOSA trial<\/strong> for<strong> IHL-42X <\/strong>in <a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-market\"><strong>obstructive sleep apnea (OSA)<\/strong><\/a> will proceed, following FDA protocol authorization under the company\u2019s IND. IHL-42X is Incannex\u2019s lead asset, and the trial marks a key advancement toward addressing a condition affecting nearly one billion people globally, with no currently approved oral drug therapies. The trial design will leverage a U.S.-only strategy and existing Phase II infrastructure to expedite execution.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe progression of RePOSA into Phase III represents a major milestone for Incannex and our shareholders,\u201d said <\/em><strong><em>Joel Latham, President and CEO of Incannex.<\/em><\/strong><em> \u201cIHL-42X is a high-value asset targeting one of the most prevalent and under-treated conditions globally, OSA. With FDA clearance, a streamlined study design, and the drug product already manufactured, we are uniquely positioned to execute efficiently and deliver meaningful value. IHL-42X has the potential to become the first FDA-approved oral therapy for obstructive sleep apnea, and we believe it could transform the treatment paradigm for millions of patients across the globe.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The Phase III study will be a randomized, placebo-controlled trial over 12 months, with a 3-month head-to-head comparison against monotherapies, dronabinol, and acetazolamide. It will measure the change in Apnea-Hypopnea Index (AHI) as the primary endpoint, alongside secondary endpoints like sleep quality and patient-reported outcomes. Approximately 30 U.S. sites will participate, including 20 from Phase II.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe\u2019re building on strong foundations. The ability to carry forward much of the operational infrastructure from Phase II gives us a significant edge in both speed and cost,\u201d added Latham. \u201cAs we prepare to report Phase II topline results in the coming weeks, we\u2019re excited by the growing momentum around IHL-42X and the commercial conversations already underway. This is a high-impact opportunity, and we remain focused on delivering the strongest outcome possible for our shareholders.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-kura-oncology-and-kyowa-kirin-gain-fda-priority-review-for-ziftomenib-nda-in-npm1-mutant-aml\"><span class=\"ez-toc-section\" id=\"Kura_Oncology_and_Kyowa_Kirin_Gain_FDA_Priority_Review_for_Ziftomenib_NDA_in_NPM1-Mutant_AML\"><\/span>Kura Oncology and Kyowa Kirin Gain FDA Priority Review for Ziftomenib NDA in NPM1-Mutant AML<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Kura Oncology, Inc. and Kyowa Kirin Co., Ltd.<\/strong> announced that the FDA has accepted Kura\u2019s New Drug Application (NDA) for ziftomenib as a treatment for adult patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market\"><strong>relapsed or refractory (R\/R) acute myeloid leukemia (AML)<\/strong><\/a> with an NPM1 mutation. The NDA has been granted Priority Review, with a PDUFA target action date of November 30, 2025. If approved, ziftomenib would become the first menin inhibitor authorized for this genetically defined AML subgroup.<\/p>\n\n\n\n<p>The NDA submission is based on positive results from the<strong> Phase II KOMET-001<\/strong> registrational trial, which achieved its primary endpoint of complete remission (CR) plus CR with partial hematological recovery (CRh). Ziftomenib demonstrated a favorable safety profile with limited myelosuppression and only 3% treatment-related discontinuations. The investigational therapy has previously received Breakthrough Therapy, Fast Track, and Orphan Drug Designations from the FDA.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA\u2019s acceptance of our New Drug Application marks a significant milestone for Kura and Kyowa Kirin and, more importantly, for patients living with this genetic subset of AML, who face an aggressive form of the disease with few treatment options,\u201d said <\/em><strong><em>Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology<\/em><\/strong><em>. \u201cThis achievement reflects the strength of the clinical data for ziftomenib as well as the incredible commitment of our teams. Along with our partners at Kyowa Kirin, we look forward to continuing to work closely with the FDA throughout the review process and to prepare for the anticipated launch of this treatment, which holds potential to meaningfully impact the lives of patients and their families.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cAdult R\/R NPM1-m AML patients face a significantly poor prognosis, highlighting the urgent need for innovative treatment options that can improve their outcomes,\u201d said <\/em><strong><em>Takeyoshi Yamashita, Ph.D., Executive Vice President and Chief Medical Officer of Kyowa Kirin<\/em><\/strong><em>. \u201cThe acceptance of this NDA is a crucial step in our ongoing efforts to explore and evaluate various therapeutic strategies for AML through our comprehensive clinical trials. Our dedicated teams at Kyowa Kirin and Kura are fully committed to working tirelessly to ensure that, once approved, ziftomenib is made available to AML patients as quickly as possible. We recognize the importance of this endeavor and are excited about the possibility of making a meaningful impact on the lives of those affected by this challenging disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gsk-s-nda-for-linerixibat-accepted-by-fda-for-pbc-related-cholestatic-pruritus\"><span class=\"ez-toc-section\" id=\"GSKs_NDA_for_Linerixibat_Accepted_by_FDA_for_PBC-Related_Cholestatic_Pruritus\"><\/span>GSK\u2019s NDA for Linerixibat Accepted by FDA for PBC-Related Cholestatic Pruritus<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>GSK plc <\/strong>announced that the FDA has accepted its <strong>New Drug Application (NDA) <\/strong>for <strong>linerixibat<\/strong>, a targeted ileal bile acid transporter (IBAT) inhibitor, for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/cholestatic-pruritus-market\"><strong>cholestatic pruritus<\/strong><\/a><strong> in patients with <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-biliary-cholongitis-pbc-market\"><strong>primary biliary cholangitis (PBC)<\/strong><\/a>. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 24, 2026.<\/p>\n\n\n\n<p>The NDA is supported by positive results from the <strong>Phase III GLISTEN trial<\/strong>, which met its primary and key secondary endpoints. The study demonstrated a rapid, significant, and sustained reduction in cholestatic pruritus and itch-related sleep interference compared to placebo. The safety profile of linerixibat remained consistent with earlier findings and its IBAT inhibition mechanism.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA\u2019s acceptance of this file is an important milestone in the development of linerixibat. We believe that linerixibat has the potential to make a difference in the lives of patients living with relentless itch associated with PBC and its related sleep interference. These are debilitating symptoms which currently have very limited treatment options,\u201d said <\/em><strong><em>Kaivan Khavandi, SVP, Global Head, Respiratory, Immunology &amp; Inflammation R&amp;D, GSK<\/em><\/strong><em>.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Linerixibat has not yet been approved for use in any country. If approved, it would offer a novel treatment option for a rare, burdensome condition with high unmet medical need.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ascendis-pharma-s-transcon-cnp-receives-fda-priority-review-for-achondroplasia\"><span class=\"ez-toc-section\" id=\"Ascendis_Pharmas_TransCon_CNP_Receives_FDA_Priority_Review_for_Achondroplasia\"><\/span>Ascendis Pharma&#8217;s TransCon CNP Receives FDA Priority Review for Achondroplasia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Ascendis Pharma A\/S<\/strong> announced that the <strong>FDA <\/strong>has accepted its <strong>New Drug Application (NDA)<\/strong> for <strong>TransCon CNP (navepegritide)<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/achondroplasia-market\"><strong>children with achondroplasia<\/strong><\/a>, a rare genetic bone growth disorder. The application has been granted Priority Review, and the FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025. Notably, the FDA does not currently plan to convene an advisory committee meeting to discuss the application.<\/p>\n\n\n\n<p>TransCon CNP is an investigational once-weekly prodrug of C-type natriuretic peptide (CNP) designed to deliver sustained exposure to active CNP, enabling continuous inhibition of the overactive FGFR3 pathway, the underlying cause of achondroplasia. In Phase II clinical trials, TransCon CNP showed a statistically significant improvement in annualized growth velocity, meeting its primary endpoint. Additionally, the treatment demonstrated multiple improvements beyond linear growth, including better lower limb alignment, spinal canal dimensions, and muscle strength, with a safety and tolerability profile similar to placebo.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cToo many profound medical needs endure for people living with achondroplasia,\u201d said <\/em><strong><em>Chandler Crews<\/em><\/strong><em>, Founder of The Chandler Project. \u201cTherapies that could address some of the underlying, serious complications of achondroplasia offer welcome potential to improve health outcomes beyond what currently approved therapies and interventions offer.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cPeople living with achondroplasia and their physicians have expressed an urgent need for a meaningful treatment option to address the complications of achondroplasia,\u201d said <\/em><strong><em>Aimee Shu, M.D.<\/em><\/strong><em>, Executive Vice President of Endocrine &amp; Rare Disease Medical Sciences and Chief Medical Officer at Ascendis Pharma. \u201cWe look forward to working with the FDA during its review to make TransCon CNP available as quickly as possible.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>If approved, TransCon CNP could become a new standard of care for children with achondroplasia by targeting not just growth but also the broader skeletal and functional complications of the condition.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beam Therapeutics Secures FDA Orphan Drug Designation for BEAM-302 in AATD Beam Therapeutics Inc. announced that the FDA has granted Orphan Drug Designation to its investigational therapy, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD). BEAM-302 is a liver-targeting lipid nanoparticle (LNP) formulation containing a guide RNA and an mRNA encoding a base editor [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":32359,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[3868,21676,21675,18089,22440,22442,19857,19855,19858,204,349,420,2858,19378,639,18507,20349,20346,5789],"industry":[17225],"therapeutic_areas":[17237,17239,17238,17228,17506],"class_list":["post-32358","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-achondroplasia","tag-achondroplasia-market","tag-achondroplasia-treatment","tag-acute-myeloid-leukemia","tag-acute-myeloid-leukemia-drugs","tag-acute-myeloid-leukemia-market","tag-alpha-1-antitrypsin-deficiency-market","tag-alpha-1-antitrypsin-deficiency-treatment","tag-alpha-1-antitrypsin-deficiency-treatment-market","tag-delveinsight","tag-latest-pharma-news","tag-news","tag-obstructive-sleep-apnea","tag-obstructive-sleep-apnea-pipeline","tag-pharma-news","tag-primary-biliary-cholangitis","tag-primary-biliary-cholangitis-market","tag-primary-biliary-cholangitis-treatment","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-gastroenterology","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology","therapeutic_areas-sleep-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Beam, Incannex, Kura<\/title>\n<meta name=\"description\" content=\"Beam\u2019s BEAM-302; Incannex\u2019s IHL-42X; Kura and Kyowa Kirin\u2019s Ziftomenib; GSK\u2019s Linerixibat; Ascendis\u2019 TransCon CNP\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Beam, Incannex, Kura\" \/>\n<meta property=\"og:description\" content=\"Beam\u2019s BEAM-302; Incannex\u2019s IHL-42X; Kura and Kyowa Kirin\u2019s Ziftomenib; GSK\u2019s Linerixibat; Ascendis\u2019 TransCon CNP\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-03T11:48:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-03T11:48:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/03171737\/3-6-2025-feature.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Beam, Incannex, Kura","description":"Beam\u2019s BEAM-302; Incannex\u2019s IHL-42X; Kura and Kyowa Kirin\u2019s Ziftomenib; GSK\u2019s Linerixibat; Ascendis\u2019 TransCon CNP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Beam, Incannex, Kura","og_description":"Beam\u2019s BEAM-302; Incannex\u2019s IHL-42X; Kura and Kyowa Kirin\u2019s Ziftomenib; GSK\u2019s Linerixibat; Ascendis\u2019 TransCon CNP","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-06-03T11:48:01+00:00","article_modified_time":"2025-06-03T11:48:50+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/03171737\/3-6-2025-feature.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura","name":"Pharma News | Beam, Incannex, Kura","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/03171737\/3-6-2025-feature.png","datePublished":"2025-06-03T11:48:01+00:00","dateModified":"2025-06-03T11:48:50+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Beam\u2019s BEAM-302; Incannex\u2019s IHL-42X; Kura and Kyowa Kirin\u2019s Ziftomenib; GSK\u2019s Linerixibat; Ascendis\u2019 TransCon CNP","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-beam-incannex-kura#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/03171737\/3-6-2025-feature.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/03171737\/3-6-2025-feature.png","width":772,"height":482,"caption":"pharma-news-for-beam-incannex-kura"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/03171737\/3-6-2025-feature-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">achondroplasia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Achondroplasia Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Achondroplasia Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute Myeloid Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute myeloid leukemia drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute Myeloid Leukemia market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">alpha-1 antitrypsin deficiency market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">alpha-1 antitrypsin deficiency treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">alpha-1 antitrypsin deficiency treatment market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">obstructive sleep apnea<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Obstructive Sleep Apnea pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Primary Biliary Cholangitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Primary Biliary Cholangitis Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Primary Biliary Cholangitis Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">achondroplasia<\/span>","<span class=\"advgb-post-tax-term\">Achondroplasia Market<\/span>","<span class=\"advgb-post-tax-term\">Achondroplasia Treatment<\/span>","<span class=\"advgb-post-tax-term\">Acute Myeloid Leukemia<\/span>","<span class=\"advgb-post-tax-term\">Acute myeloid leukemia drugs<\/span>","<span class=\"advgb-post-tax-term\">Acute Myeloid Leukemia market<\/span>","<span class=\"advgb-post-tax-term\">alpha-1 antitrypsin deficiency market<\/span>","<span class=\"advgb-post-tax-term\">alpha-1 antitrypsin deficiency treatment<\/span>","<span class=\"advgb-post-tax-term\">alpha-1 antitrypsin deficiency treatment market<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">obstructive sleep apnea<\/span>","<span class=\"advgb-post-tax-term\">Obstructive Sleep Apnea pipeline<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Primary Biliary Cholangitis<\/span>","<span class=\"advgb-post-tax-term\">Primary Biliary Cholangitis Market<\/span>","<span class=\"advgb-post-tax-term\">Primary Biliary Cholangitis Treatment<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 12 months ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Jun 3, 2025","modified":"Updated on Jun 3, 2025"},"absolute_dates_time":{"created":"Posted on Jun 3, 2025 5:18 pm","modified":"Updated on Jun 3, 2025 5:18 pm"},"featured_img_caption":"pharma-news-for-beam-incannex-kura\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32358"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32358\/revisions"}],"predecessor-version":[{"id":32360,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32358\/revisions\/32360"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32359"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32358"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32358"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}